Enry’s Island Secures €20 Million from LDA Capital to Scale the First Accelerator in the Metaverse
17.5.2022 17:00:00 EEST | Business Wire | Press release
Enry’s Island is delighted to announce that they have secured a Euro 20 million capital commitment from LDA Capital, an alternative investment group with expertise in complex, cross-border transactions around the globe, based in Los Angeles, California. Adding to the year’s success, this capital commitment comes just as Enry’s Island prepares to operate on international markets, making them a rising star in the incubation and acceleration world, one of the hottest industries of this current economic environment.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220517005729/en/
LDA Capital lands on Enry's Island, with a € 20M round (Graphic: Business Wire)
“We are excited about our partnership with LDA Capital”, says Luigi Valerio Rinaldi, founder and CEO of Enry’s Island. Over the course of the next few months, the Company will transform into a “S.p.a.” (Italian joint stock company), “allowing the business to scale even faster with LDA’s flexible financing package. We are sure that the relationship with LDA will continue in a mutually gratifying way in the medium and long term horizon, allowing the horses in our stable to become unicorns.”
This new capital commitment of funding will be used to scale Enry’s Island phygital capabilities. Specifically, the areas that the company will focus on are:
- Expansion in the Metaverse and physical spaces (thanks to Enry’s Island portfolio company Rinascimento 5)
- International reach increase, thanks to Enry’s Island Local Companies
- Add 12x to 36x financial value within 3-5 years
- Consolidating a worldwide standard protocol for the assessment and evaluation of the startups, based on Enry’s Model intellectual property (IP)
At the forefront of the industry, Enry’s Island is the first Incubation & Acceleration Metaverse (# 1 incubator & accelerator in Italy, & # 6 in Europe according to Crunchbase Q4/2021), with local companies in US, UK, Italy, Spain, Ireland, Africa, a global community of more than 800 stakeholders who include entrepreneurs, investors, and professionals and 30 startups, thoroughly assessed and evaluated based on Enry’s Model, the patented intellectual property the whole organization, processes and tool of Enry’s Island is based on. The Enry’s Model is also part of the “Enry’s Theory” manual of business management, published by MacGraw-Hill.
About LDA Capital
LDA Capital is a global alternative investment group with expertise in cross border transactions worldwide. Our team has dedicated their careers to international & cross border opportunities having collectively executed over 250 transactions in both the public and private middle markets across 43 countries with aggregate transaction values of over US$11 billion. For more information please visit: www.ldacap.com; For inquires please email: info@ldacap.com.
About Enry’s Island
- 15 years of experience in the management of very early stage startups, with a mortality rate of only 10% (against 90% which is the industry average)
- 12-month incubation and acceleration programs, totally customized to the needs of startups, with investments of € 200k in operational services (not just mentorship)
- Proprietary patent, Enry's Model, which allows for the evaluation of company performance and value; Enry's Model is also the subject of a McGrawHill manual (which, in view of its success in Europe, has been translated for the US market);
- Explosive scale up in the last 3 years, going from 8 to 25 companies, from €2M to €40M in portfolio value, from a community of 30 to 800 stakeholders;
- full remote and totally distributed organization, which has allowed Enry’s Island to grow during the last 2 years of pandemic;
- A revolutionary corporate architecture, which includes local companies in Ita, US, UK, Africa, Ibiza, Ireland and upcoming openings in the Far East, that do not replicate, but specialize and scale the different EI best practices in the different countries.
- High information symmetry, given that the whole EI community uses a revolutionary Saas platform (hui.land), which guarantees efficiency and effectiveness in business management and business risk containment; HUI provides KPIs to all internal and external stakeholders, allowing investors to invest directly in target companies through HUI (thanks to crowdfunding campaigns in Europe, US and Canada), directly through HUI;
- A revolutionary vision and management of space, both physical (having eliminated any physical location, as if it were in a DAO, but using a network of hosts with ideal characteristics for remote working in places with a high quality of life, such as villages, natural areas) and metaverse space (EI has started investing in the metaverse, building its first building in Cryptovoxels and having launched the first investor day entirely in metaverse https://www.cryptovoxels.com/parcels/7328)
Visit www.enrysisland.com and discover why Enry’s Island has ignited interest from all over the world.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220517005729/en/
Contact information
Investor relations:
Enry’s Island - Benefit Company
Gabriele Vedani
Investor Relations Manager
gabriele.vedani@enrysisland.com
0039 335 6625055
website: enrysisland.com
website: metaverse.enrysisland.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 12:47:00 EEST | Press release
Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food products. Within this inspiring premise, Good Food Makers confirms itself as one of the main levers f
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 11:16:00 EEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
